Observe Medical Yönetim

Yönetim kriter kontrolleri 1/4

Observe Medical CEO'su Jorgen Mann, Feb2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.2% doğrudan sahiptir ve bu hisselerin değeri € 14.74K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 4.8 yıldır.

Anahtar bilgiler

Jorgen Mann

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jorgen Mann

less than a year

Görev süresi

Mr. Jørgen Mann was Chief Commercial Officer of Observe Medical ASA from January 2023 until 2024 and serves as it's Interim Chief Executive Officer since February 2024. He has experience in sales and senio...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rune Nystad	Chief Development Officer	less than a year	NOK 3.11m	0.47% € 33.7k
Jorgen Mann	Interim Chief Executive Officer	less than a year	Veri yok	0.20% € 14.7k
Johan Fagerli	Interim Chief Financial Officer	less than a year	Veri yok	0.10% € 7.4k

0.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: OM5A 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Terje Bakken	Chairman of the Board	5.4yrs	NOK 300.00k	Veri yok
Kathrine E. Andreassen	Director	5.4yrs	NOK 225.00k	0.35% € 25.6k
Jan van Der Linden	Member of Advisory Board	4.8yrs	Veri yok	Veri yok
Anders Ternhag	Member of Advisory Board	4.8yrs	Veri yok	Veri yok
Eskild Endrerud	Independent Director	2.4yrs	NOK 255.00k	0.41% € 29.8k
Line Tonnessen	Independent Director	2.4yrs	NOK 265.00k	0.38% € 27.5k

4.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: OM5A 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Observe Medical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Observe Medical Asa Announces CFO Changes

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Recent updates

First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023)

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Observe Medical Asa Announces CFO Changes

New major risk - Financial position

New minor risk - Financial data availability

New major risk - Shareholder dilution

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

No independent directors

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA Announces Executive Appointments

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: €2.84

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: €1.42

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: €1.24

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: €1.04

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: €1.09

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: €1.16

First half earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi